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Lassa fever virushemorrhagic fever (HF) disease in humans for which there are no licensed
vaccines, and current therapy is limited to the use of ribavirin (Rib) that is only partially effective and
associated with signiﬁcant side effects. In addition, compelling evidence indicates that the prototypic
arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical
signiﬁcance. Therefore, it is important to develop novel and effective anti-arenaviral drugs. The arenavirus
Z protein is the driving force of arenavirus budding, and PPPY and PTAP late (L) domain motifs within Z are
critical for Z-mediated budding, which involves the interaction of Z with a variety of host cellular factors.
Compounds capable of inhibiting these virus–host cell interactions represent candidate anti-arenaviral drugs.
The identiﬁcation of these candidate compounds would be facilitated by the availability of a Z budding assay
amenable to high-throughput screens (HTS). To this end, we have developed a novel assay that allows for
rapid and quantitative assessment of Z-mediated budding. We provide evidence that this novel assay is
amenable to HTS to identify small molecule inhibitors of Z-mediated budding, as well as to uncover cellular
genes contributing to arenavirus budding.
© 2008 Elsevier Inc. All rights reserved.Introduction
Several arenaviruses, chieﬂy Lassa virus (LASV) in West Africa and
Junin virus (JUNV) in South America, cause severe hemorrhagic fever
(HF) disease in humans (Geisbert and Jahrling, 2004; McCormick and
Fisher-Hoch, 2002; Peters, 2002). In addition, increasing evidence
indicates that LCMV congenital infections have a signiﬁcant contribu-
tion to neonatal chorioretinitis and a variety of fetal abnormalities
including hydrocephalus (Barton et al., 2002; Jahrling and Peters,
1992; Mets et al., 2000). Morever, LCMV may pose a serious risk to
immunocompromised individuals as reﬂected by cases of fatal LCMV
disease associated with transplantation in the USA (Barton, 2006) and
Australia (Palacios et al., 2008). No licensed anti-arenavirus vaccines
are available, and current anti-arenavirus therapies are limited to the
use of the nucleoside analogue ribavirin (Rib), which is only partially
effective and often associated with severe side effects including
anemia and birth defects (McKee et al., 1988). Therefore, it is
important to develop novel effective antiviral strategies to combat
arenaviruses. To this end, recently developed arenavirus reverse
genetics systems (Flatz et al., 2006; Hass et al., 2004; Lopez et al.,
2001; Sanchez and de la Torre, 2006) have provided investigators with
novel, powerful tools to facilitate the identiﬁcation of compounds that.
l rights reserved.target speciﬁc steps of the arenavirus life cycle and represent novel
candidate antivirals to combat pathogenic arenaviruses.
Arenaviruses are enveloped viruses with a bisegmented, single-
stranded, negative sense (NS) RNA genome (Buchmeier et al., 2007).
Each of the two segments uses an ambisense coding strategy to direct
the synthesis of two polypeptides. The large segment (L, 7.2 kb)
encodes a small (90–99aa, 12 kDa) RING-ﬁnger protein called Z and
the RNA-dependent RNA polymerase (L protein), while the small
segment (S, 3.4 kb) encodes the nucleoprotein (NP) and glycoprotein
precursor (GPC). L and NP are the minimal viral trans-acting factors
required for virus RNA replication and gene expression (Lee et al.,
2000), whereas production of infectious particles also requires GP and
Z (Lee et al., 2002). Post-translational cleavage of GPC generates the
three components that form the GP complex (GPc): the stable signal
peptide (SSP, 58aa), GP1 (Mr 40–46 kDa), and GP2 (Mr 35 kDa)
(Buchmeier and Oldstone, 1979; Kunz et al., 2003; Pinschewer et al.,
2003; Strecker et al., 2003; York et al., 2004). Trimers of GP1/GP2
associate via ionic interactions to form the spikes that decorate the
virus surface (Eschli et al., 2006). GP1 is located at the top of the spike
and mediates virus interactions with host cell surface receptors, while
GP2 mediates membrane fusion. Virus replication is conﬁned to the
cytoplasm of infected cells and budding of progeny virus occurs at the
plasma membrane (Borio et al., 2002; Buchmeier et al., 2007; Dalton
et al., 1968; Murphy et al., 1970).
Z has been shown to be the driving force of arenavirus budding
(Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006), and is the
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enveloped NS riboviruses. These M proteins function to bridge the
virus ribonucleoprotein (RNP) core with other viral components,
including virus surface glycoproteins, to assemble mature infectious
particles whose budding from infected cells is often directed by the
interaction of M with a variety of cellular proteins (Lenard, 1996).
Consistent with its M-like role, Z interacts with both the NP (Eichler et
al., 2004) and the GPc of arenaviruses (Capul et al., 2007) and contains
PPPY and PTAP late (L) domain motifs (Perez et al., 2003) that have
been shown to play a key role in the budding activity of several
retrovirus gag proteins (Garrus et al., 2001;Martin-Serranoet al., 2001;
VerPlank et al., 2001) andMproteins fromvarious RNAviruses (Craven
et al.,1999). Myristoylation of Z at its second position glycine also plays
a critical role in membrane targeting, association with the GPc, and
budding (Capul et al., 2007; Perez et al., 2004; Strecker et al., 2006). Z
has also been implicated in interactions, via its RING domain, with
several cellular proteins including PML (Borden et al., 1998), PRH
(Topcu et al., 1999), and eIF4E (Campbell Dwyer et al., 2000). These
interactions suggest that Z might interfere with cellular processes in
arenavirus infected cells, but the precise mechanism(s) underlying
these Z-cellular protein interactions and their biological implications
remain poorly understood. The identiﬁcation of Z-interacting cellular
proteins required for Z-mediated budding will provide a deeper
understandingof this essential step in the arenavirus life cycle andmay
uncover novel targets for the design of anti-arenaviral compounds.
As with many other characterized bona ﬁde viral budding
proteins (VBP), Z-mediated budding involves its interaction with
host cell proteins including members of the multivesicular body
pathway such as Tsg101 (Perez et al., 2003; Strecker et al., 2003;
Urata et al., 2006). Therefore, disrupting these interactions with small
molecule compounds would be predicted to reduce Z-mediated
budding and consequently result in inhibition of virus propagation
within the infected host. The identiﬁcation of small molecule
inhibitors of Z-mediated budding would beneﬁt from using an
assay to rapidly and quantitatively assess Z budding activity that
would be amenable to HTS. Such an assay could also be adapted toFig. 1. Luciferase activity in CL and TCS of cells transfected with LASV-Z-FLuc chimera. Pla
transfected into 293T cells in a 96-well plate and either cell lysates (CL, panel A) or tissue cul
measured for 25% of total TCS volume, and the values were multiplied by four to reﬂect activ
signal scale between cells and TCS. Cell lysates were also examined for FLuc protein express
Detection of FLuc in CL by Western blot. Lane assignments are indicated in the ﬁgure.siRNA HTS, which could uncover additional cellular proteins that are
involved in Z-mediated budding.
Bona ﬁde VBP, including many M proteins, often have the ability to
form virus-like particles (VLP) when expressed independently of
virus infection or other virus proteins (Harty et al., 2000; Perez et al.,
2003). Therefore, the detection and quantitation of VBP-containing
VLP present in tissue culture supernatants (TCS) of VBP-transfected
cells has been frequently used to assess VBP-mediated budding.
Experimentally, this is done by harvesting VLP from TCS by
ultracentrifugation and subsequent detection of VBP (Patch et al.,
2007) by Western blotting or immunoprecipitation of VBP-containing
VLP in metabolically-labeled cells (Harty et al., 2000). These methods
were used to demonstrate that Z was the driving force of arenavirus
budding (Perez et al., 2003; Strecker et al., 2003); however, these
assays are not suitable for HTS.
Recent work has documented the use of a ﬁreﬂy luciferase (FLuc)-
based assay to assess the budding of Ebola virus VP40 (McCarthy et al.,
2006). However, a VP40-FLuc fusion protein that appeared to be
incorporated into VLPwas not active, and luciferase activity associated
with VLP was due to incorporation of FLuc into VP40 and GP-
containing VLP by mechanisms that remain uncharacterized. These
results raised some concerns regarding the value of the assay to
measure the speciﬁc budding activity of Ebola virus VP40. In contrast,
here we present data showing that a chimeric LASV-Z protein fused at
its C-terminus to Gaussia luciferase retained wildtype Z budding
activity that could be measured by determining levels of GLuc in TCS
of Z-GLuc-transfected cells. Levels of GLuc in TCS were dependent on
the budding activity of Z, and the dynamic range of the assay was
suitable for HTS based on the Z' score of the assay. This novel cell-
based luciferase assay to quantify Z-mediated budding performedwell
in proof-of-concept experiments assessing inhibition of Z-mediated
budding by a myristoylation inhibitor, or siRNA mediated knockdown
of Tsg101. These ﬁndings indicate that this newly developed budding
assay should be instrumental for both chemical and genetic HTS
aimed at identifying candidate inhibitors of arenavirus budding and
additional cellular genes contributing to arenavirus budding.smids directing the expression of the indicated LASV-Z-FLuc chimeric proteins were
ture supernatants (TCS, panel B) were assayed for luciferase activity. Activity in TCS was
ity of 100% of TCS. Transfections were done in quadruplicate. Note the difference in the
ion levels by Western blot (panel C). (A) FLuc activity in CL. (B) FLuc activity in TCS. (C)
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Budding activity of chimeric Z-luciferase proteins
The FLuc protein (550aa) has been extensively used as a reporter
both in vitro (Stankunas et al., 2007) and in vivo (Gross and Piwnica-
Worms, 2005). We therefore evaluated its use for the development of
an assay to assess LASV-Z-mediated budding. We reasoned that fusion
of FLuc to the C-terminus of LASV-Z would result in a chimeric protein
LASV-Z(WT)-FLuc whose budding activity could be determined by
measuring levels of FLuc activity in TCS of LASV-Z(WT)-FLuc-
transfected cells. Likewise, we predicted that fusion of FLuc to the C-
terminus of the G2A mutant of LASV-Z should result in a chimeric
LASV-Z(G2A)-FLuc protein with severe impaired budding activity due
to the lack of myristoylation required for Z-mediated budding (Perez
et al., 2004; Strecker et al., 2006). To examine this, we evaluated the
levels of FLuc activity in cell lysates and TCS from cells transfected
with either LASV-Z(WT)-FLuc or LASV-Z(G2A)-FLuc. We observed
similar levels of FLuc activity in total cell lysates of cells transfected
with either LASV-Z(WT)-FLuc or LASV-Z(G2A)-FLuc, which were
about 2-fold lower than levels observed in FLuc-transfected cells
(Fig. 1A). These differences correlated well with levels of protein
expression as assessed by western blotting (Fig. 1C). FLuc activity in
TCS correlated with the predicted budding activity of the correspond-
ing Z fusion protein (Fig. 1B), but the difference between LASV-Z(WT)-
FLuc and LASV-Z(G2A)-FLuc was at best only 2-fold. We also observed
that in LASV-Z(WT)-FLuc-transfected cells, levels of FLuc activity were
about 1000-fold lower in TCS compared to cell lysates. These results
indicated that fusion of FLuc to the C-terminus of Z resulted in a
dramatic impairment of Z budding activity, thereby preventing the use
of LASV-Z(WT)-FLuc for the development of a reporter for Z-mediated
budding.Fig. 2. Luciferase activity in CL and TCS of cells transfected with LASV-Z-GLuc chimera. 293T c
a 96-well plate. At 48 h post-transfection, TCS and CL were collected for measurement of GLu
VLP were prepared from TCS as described (Perez et al., 2003). CL and VLPs were probed for Z i
in TCS. (C) Z-GLuc detected in VLPs using standard centrifugation protocol.We considered that the large size (550aa) of FLuc compared to Z
(99aa), might have contributed to impaired Z budding activity. We
therefore explored the use of the smaller Gaussia luciferase (GLuc,
185aa) (Tannous et al., 2005). To this end, we tested fusions of LASV-Z
(WT) or LASV-Z(G2A) to GLuc. The presence of a secretory signal
peptide (SP) at the N-terminus of GLuc mediates its efﬁcient secretion
from cells (Knappskog et al., 2007; Tannous et al., 2005). Accordingly,
TCS from GLuc-transfected cells exhibit 1000-fold higher levels of
luciferase activity compared to TCS from cells transfected with a
version of GLuc lacking its SP (GLuc-ΔSP). We therefore reasoned that
replacing the GLuc SP with LASV-Z(WT) would result in release of the
LASV-Z(WT)-GLuc protein into TCS that was dependent on the
budding activity of Z. Further, we predicted that fusion of the LASV-
Z G2A myristoylation mutant to GLuc-ΔSP should result in a fusion
protein (LASV-Z(G2A)-GLuc) with impaired budding activity, which
would be reﬂected in reduced levels of luciferase activity in TCS from
LASV-Z(G2A)-GLuc-transfected cells. We were also concerned
whether overexpression of such chimeras might perturb cell viability.
To this end, we measured cell viability using a ﬁreﬂy luciferase-based
ATP assay and normalized ATPmeasurements of cells transfected with
the GLuc constructs and Z-GLuc chimeras to cells transfected with
empty vector. Since FLuc has different substrate speciﬁcity than GLuc,
the viability assay is not inﬂuenced by the presence of GLuc in cells
(see Materials and methods).
TCS from cells expressing LASV-Z(WT)-GLuc showed levels of GLuc
activity in TCS that were 8-fold higher compared to cells expressing
LASV-Z(G2A)-GLuc (Fig. 2B). Further, TCS luciferase activities of GLuc-
ΔSP transfected and LASV-Z-(G2A)-GLuc were similar; indicating that
replacement of the signal peptide with a budding-defective Z could
not rescue release of GLuc from cells. GLuc activity levels correlated
well with levels of Z-GLuc protein detected in VLPs recovered from
TCS (Fig. 2C).ells were transfected with plasmids to express the indicated proteins in quadruplicate in
c activity. In a separate experiment cells were transfected in a six-well plate format and
nwestern blots using antibodies to GLuc and HA. (A) GLuc activity in CL. (B) GLuc activity
Fig. 3. Calculation of Z' using LASV-Z-GLuc fusion. Cells were transfected overnight with
the indicated plasmids in six-well plates. Transfection medium was then changed to
complete cell culture medium and cells were allowed to recover for 8 h, followed by
preparation of single-cell suspension and seeding 4×104 cells in 96-well plates. TCS and
cells were collected 48 h later for measurement of GLuc activity and cell viability,
respectively. Five replicate wells were measured to calculate Z'. (A) Cell viability as
assessed by ATP content. (B) GLuc activity from TCS, and the Z' score is shown above the
positive (LASV-Z(WT)-GLuc) and negative (LASV-Z(G2A)-GLuc) controls.
Fig. 4. Effect of 2-OHM on LASV-Z-GLuc budding. 293T cells were transfected (quadruplic
at the same concentration present in 2-OHM-treated cells. At 48 h post-transfection, cells
GLuc measurement. (A) Cell viability. (B) Measurement of GLuc activity in CL. (C) Meas
LASV-Z(G2A)-GLuc budding, where budding activity of LASV-Z(WT)-GLuc is set at 100.
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assay to rapidly and quantitatively assess Z-mediated budding. We
then asked whether LASV-Z-GLuc could be used to develop a HTS
assay. For this, we calculated our assay Z' score (Z' =1− [(3σc++3σc−) /
|3μc+−3μc−|]) (Zhang et al., 1999), which is a measure of the quality and
robustness of a HTS assay attributable to the standard deviation
between multiple reads (Singh et al., 2004). Z' values depend on the
sum of the standard deviations of positive and negative controls (σc+
and σc−, respectively) as well as the difference between the mean
activities of these controls (μc+ and μc−). Therefore, ideal assay
conditions would show small variations within each control and a
large difference between the controls. To determine the Z' value of our
assay, we used measurements of GLuc activity in TCS from cells
expressing LASV-Z(WT)-GLuc or LASV-Z(G2A)-GLuc as positive or
negative controls, respectively. In two independent experiments the Z'
score of our assaywas N0.5 (Fig. 3), a value that corresponds to an assay
with excellent properties forHTS (Singh et al., 2004; Zhanget al.,1999).
Z-GLuc budding is susceptible to myristoylation inhibitors
Based on the critical role of myristoylation in Z-mediated budding
(Perez et al., 2004; Strecker et al., 2006), we predicted that LASV-Z
(WT)-GLuc would be susceptible to myristoylation inhibitors. To
examine this we transfected 293T cells with LASV-Z(WT)-GLuc in the
presence or absence of 2-hydroxymyristic acid (OHM), a myristoyla-
tion inhibitor. While GLuc activity was decreased by approximately
2-fold in cells expressing GLuc-ΔSP, LASV-Z(WT)-GLuc, or LASV-Z
(G2A)-GLuc (Fig. 4B), we found that the activity in TCS from LASV-Zate) in a 96-well plate in the presence of 2-OHM (100 μM) or vehicle alone (DMSO)
were measured for viability using CellTiter Glo (Promega) and TCS was collected for
urement of GLuc activity in TCS. (D) Comparison of LASV-Z(WT)-GLuc budding and
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ment with OHM (Fig. 4C), a ﬁnding consistent with published results
(Perez et al., 2004; Strecker et al., 2006). Further, when we compared
LASV-Z(WT)-GLuc to LASV-Z(G2A)-GLuc directly (Fig. 4D), we found
that release of LASV-Z(G2A)-GLuc into TCS was 87% decreased
compared to LASV-Z(WT)-GLuc, which was consistent with previous
results (Perez et al., 2004; Strecker et al., 2006).
To further examine the speciﬁcity of the effect of OHM on Z-GLuc
budding, we measured the effect of OHM on GLuc expression and
secretion. Cells were separately transfectedwithWTGLuc and treated,
or not, with OHM. Cell lysates were measured for either GLuc activity
or ATP content (to assess cell viability), and TCS were collected for
GLuc activity. After adjusting for cell viability, levels of GLuc activity
were two-fold increased in lysates from OHM-treated cells compared
to untreated cells (Fig. 4B), whereas in TCS, GLuc activity was
diminished by 26% in the presence of OHM (Fig. 4C).Fig. 5. Z-GLuc fusion is susceptible to knockdown of Tsg101. Cells were transfected in
triplicatewells with siRNA directed against Tsg101, or with a control siRNA. At 24 h post-
transfection, cells were transfected to express LASV-Z(WT)-GLuc. TCS was collected for
GLuc assay 24 h after LASV-Z(WT)-GLuc transfection. (A) Activity of GLuc in TCS when
normalized for activity from LASV-Z(WT)-GLuc expressing cells in the presence of non-
speciﬁc siRNA (set to 1). (B) Cellular expression of GLuc when normalized for activity
from LASV-Z(WT)-GLuc expressing cells in the presence of non-speciﬁc siRNA (set to 1).
(C) Budding efﬁciency of LASV-Z(WT)-GLuc in the presence of Tsg101-speciﬁc siRNA
where budding efﬁciency in the presence of non-speciﬁc siRNA was set at 1. Budding
efﬁciency was calculated as follows: GLuc activity (TCS) / ([GLuc activity (TCS)]+ [ GLuc
activity (CL)]).Z-GLuc mediated budding is susceptible to RNAi knockdown of Tsg101
Previous ﬁndings have shown that Z-mediated budding involves Z
interaction with members of the MVB pathway including Tsg101
(Perez et al., 2003; Urata et al., 2006). Consequently, we predicted
LASV-Z(WT)-GLuc budding to be sensitive to knockdown of Tsg101 by
RNAi. To assess this prediction, we transfected cells with either non-
speciﬁc or Tsg101-speciﬁc siRNA then subsequently with LASV-Z
(WT)-GLuc and measured TCS GLuc activity. We observed a 30%
reduction in TCS luciferase activity from cells transfected with the
Tsg101-speciﬁc siRNA (Fig. 5A), while the corresponding cell-
associated luciferase activity was increased by 50% (Fig. 5B). When
we calculated budding efﬁciency (Fig. 5C), we found a 24% decrease,
which was consistent with previous ﬁndings (Urata et al., 2006).
Discussion
Budding of many enveloped NS RNA virus require interactions
between cellular proteins and the VBP. Interfering with these
interactions presents an opportunity to both understand the cellular
biology of virus budding and to identify potential novel antiviral
targets and drugs. We sought to develop a Z budding assay that would
facilitate the identiﬁcation of small molecule inhibitors of these
interactions and therefore arenavirus budding. To this end we tested
the use of LASV-Z-luciferase fusion proteins as tools to develop an
assay to rapidly and quantitatively measure Z-mediated budding. A
chimeric LASV-Z-FLuc protein showed 1000-fold lower activity in TCS
than in cells, indicating that only small amounts of LASV-Z-FLuc could
bud into TCS. In contrast, about 90% of GLuc activity in LASV-Z(WT)-
GLuc expressing cells was in TCS. Moreover, levels of TCS luciferase
activity were dramatically reduced (≥8-fold) in cells transfected with
LASV-Z(G2A)-GLuc compared to LASV-Z(WT)-GLuc-transfected cells.
Previously, we showed that LASV-Z tagged at its C-terminus with HA
(LASV-Z(WT)-HA) has WT Z budding activity as determined by levels
of Z present in VLP collected from TCS of transfected cells (Perez et al.,
2003). Using the same biochemical assay, we observed that LASV-Z
(WT)-HA and LASV-Z(WT)-GLuc had similar budding activity. These
results argue strongly that the LASV-Z(WT)-GLuc chimera is function-
ally equivalent to WT Z in budding activity and therefore levels of Z-
mediated budding can be assessed based on GLuc activity in TCS from
Z-GLuc-transfected cells.
The reasons why LASV-Z(WT)-FLuc was severely impaired in its
budding activity remain to be determined. However, a signiﬁcant
difference is the larger size (three times bigger) of FLuc compared to
GLuc. Notably, a TAP-tagged Z (LASV-Z(WT)-TAP) retained WT Z
budding activity (MP and JCT, unpublished data), and interestingly the
TAP tag and GLuc are similar in size (185aa and 168aa respectively),
while FLuc is 550aa. It is therefore plausible that the budding
efﬁciency of chimeric Z proteins may depend on the size of the fusion
partner added to Z.
GLuc activity from cells expressing either GLuc-ΔSP or LASV-Z
(G2A)-GLuc were 1000-fold lower than GLuc WT. These results
showed that consistent with previous results GLuc secretion requires
its SP (Tannous et al., 2005), but also that a Z mutant defective in
budding cannot functionally substitute for the SP of GLuc. We also
observed that levels of GLuc in TCS from LASV-Z(WT)-GLuc-
transfected cells were consistently lower (50–60 fold) compared to
those in TCS from GLuc WT transfected cells. Differences in the
mechanism by which GLuc and LASV-Z(WT)-GLuc are released from
cells likely contributed to these ﬁndings. The former involves
secretion mediated by the native SP in WT GLuc (Knappskog et al.,
2007), whereas the latter occurs via budding mediated by WT Z.
Together, these data indicate that GLuc release from cells depends on
the efﬁciency of SP-mediated secretion, whereas levels of released Z-
GLuc chimera proteins into TCS reﬂect the relative efﬁciency of Z-
mediated budding.
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positive and negative controls, respectively, our assay had Z' values
signiﬁcantly N0.5, thus indicating that our assay has excellent features
for its use in HTS.
We showed thatWT GLuc expression and secretionwas somewhat
affected, though modestly, by OHM (Figs. 4B and C). These results
suggest that some effects of OHM are independent of inhibiting
myristoylation. Since GLuc is released from cells via secretion, OHM
could have affected one or more steps in secretion by a mechanism
that we do not presently understand. To address the possibility that
GLuc could be myristoylated and therefore be susceptible to OHM, the
amino acid sequence for GLuc was submitted to the prediction
program NMT-The Predictor (http://mendel.imp.ac.at/myristate/
SUPLpredictor.htm), which is available through the ExPASy (Expert
Protein Analysis System) proteomics server (http://www.expasy.org/)
of the Swiss Institute of Bioinformatics (SIB). We found no myristoyla-
tion sites within GLuc (data not shown), supporting the notion that
OHM was somehow affecting secretion. We had also observed a
decrease in intracellular GLuc-ΔSP following OHM treatment (Fig. 4B).
This effect was similar to the effects of OHM on intracellular
expression of the Z-GLuc chimeras, suggesting that the effect of
OHM on intracellular Z-GLuc was likely due to effects on expression of
GLuc-ΔSP. Interestingly, these ﬁndings suggest that GLuc intracellular
expression could be used to assess pleiotropic effects of small
molecules on more general processes such as cell viability, PolII-
mediated transcription, or both, which provides this assay with an
important internal control to normalize values of Z-GLuc budding.
The susceptibility of LASV-Z(WT)-GLuc to RNAi knockdown of
Tsg101 indicates that Z-GLuc was also sensitive to disruption of late
domain function. While the effect of Tsg101-speciﬁc siRNA on Z-GLuc
budding was modest compared to previously published ﬁndings, the
results presented here reﬂect effects following a single siRNA
transfection, whereas stronger effects have been observed with two
transfections of siRNA prior to transfection with the VBP of choice
(Garrus et al., 2001; Urata et al., 2006). These results suggest that with
reﬁnement this assay could be adapted for use in siRNA-based HTS
approaches to identify additional cellular proteins necessary for Z-
mediated budding. The same screens might also identify cellular
proteins involved in Z-mediated budding via interactions in regions
outside the L-domains of Z. Therefore, cellular proteins identiﬁed
using this method would need to be evaluated for their L-domain
dependent or independent interaction with Z.
We have shown that GLuc fusion to the arenavirus LASV-Z matrix
protein results in a chimeric protein with similar budding properties
to native Z. This would allow the use of BSL2 facilities to implement
HTS aimed at identifying inhibitors of budding of LASV and HF
arenaviruses, for which use of live virus requires BSL4 facilities.
Importantly, because LASV-Z protein contains two late domain motifs,
the LASV-Z-GLuc chimera can be used to identify targets necessary for
VBP-mediated budding via either domain. Further, we think that
similar GLuc chimeras could be done with VBP from other highly
pathogenic riboviruses, making it possible to conduct assays under
BSL-2 conditions to rapidly identify inhibitors of virus budding that
might be developed into antiviral drugs. Likewise, the use of VBP-GLuc
based assays should facilitate the use of siRNA-based HTS to globally
identify host cellular proteins involved in VBP-mediated budding in
different RNA viruses, including important human pathogens.
Materials and methods
Plasmid construction
The plasmid pC-FLuc was generated by releasing the FLuc open
reading frame from pEGSH-Luc (Stratagene, La Jolla, CA) by digestion
with KpnI and SalI and cloning it into the KpnI and XhoI sites in
pCAGGS (Niwa et al., 1991). Hereafter, pCAGGS is indicated by theabbreviation pC. Plasmid pC-GLuc was made by PCR-amplifying the
Gaussia luciferase open reading frame from pCMV-hGLuc (New
England Biolabs) using the primer pair GLuc forward2 (5′-AGGGGG-
TACCGGATCCTCCTCCGGGACTGTAGGG-3′) and GLuc reverse (5′-
TGCATGCTCGAGCGGCCGCTTAGTC-3′) then cloning into pC using
KpnI and XhoI (restriction enzyme recognition sites are underlined).
Plasmid pC-LASV-Z(WT)-FLuc was made by amplifying LASV-Z
from pC-LVZ-HA (Perez et al., 2004) using OLVZ1FEco (5′-CC-
TGAATTCATGGGAAACAAGCAAGCC -3′) and LASVZ1RKpn (5′-AGG-
GGGTACCGGATCCTCCTCCGGGACTGTAGGG-3′), then cloning the PCR
product into the EcoRI and KpnI sites of pC-FLuc. Plasmid pC-LASV-Z
(G2A)-FLuc was generated by amplifying LASV-Z(G2A) from pC-LVZ
(G2A)-HA (Perez et al., 2004) using the primers OLVZG2AFEco (5′-
CCTGAATTCATGGCTAACAAGCAAGCCAAAGCC-3′) and LASVZ1RKpn
then cloning the resulting PCR product into the EcoRI and KpnI sites
of pC-FLuc. Plasmid pC-GLuc-ΔSP was generated by amplifying a
region of GLuc to replace the signal peptide as determined by SignalP
identiﬁcation of the GLuc signal peptide (Nielsen et al., 1999) with a
start codon using the primer pair GLuc SP ORF-F (5′-GGTCCAGGTAC-
CATGAAGCCCACCGAGAACAAC-3′) and GLuc-R then cloning the result-
ing PCR product into the KpnI and XhoI sites of pC. To create fusions of
LASV-Z with GLuc, the plasmid pC-GLuc-ΔSP-intermediate was ﬁrst
generated by amplifying a region of GLuc lacking the signal peptide
using the primer pair GLuc SP-forward1 (5′-GGTCCAGGTACCAAGCC-
CACCGAGAACAAC-3′) and GLuc reverse and cloning the resulting PCR
product into the KpnI and XhoI sites of pC. The plasmid pC-LASV-Z
(WT)-GLucwas generated by subcloning an EcoRI/KpnI fragment from
pC-LASV-Z(WT)-FLuc into the EcoRI and KpnI sites of pC-GLuc-ΔSP-
intermediate. The plasmid pC-LASV-Z(G2A)-GLuc was generated by
subcloning an EcoRI/KpnI fragment from pC-LASV-Z(G2A)-FLuc into
the EcoRI and KpnI sites of pC-GLuc-ΔSP-intermediate. All plasmids
were prepared using Qiagen kits and were sequenced prior to
transfection.
VLP assays
VLP assays were done as previously described (Perez et al., 2003).
Brieﬂy, 293T cells were transfected with pC-LASV-Z-HA, pC-LASV-Z-
G2A-HA, pC-LASV-Z(WT)-GLuc, or pC-LASV-Z(G2A)-GLuc using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according tomanufacturer's
instructions. Hereafter, Lipofectamine 2000 is indicated in the text
with the abbreviation LF2000. At 48–72 h post-transfection cell
lysates (CL) were collected in lysis buffer (50 mM Tris pH8.0/62.5 mM
EDTA/1% NP-40/0.4% DOC) and TCS centrifuged through a 20% cushion
at 100,000 ×g, 4 °C, for 1 h and the resulting pellet containing VLPswas
dissolved in 2× SDS sample buffer. VLPs and CL were analyzed by
western blotting using antibodies to either HA or GLuc.
Western blot analysis
Aliquots of cell lysates and VLPs were loaded onto 12% poly-
acrylamide Tris–glycine gels and run under constant voltage in Tris–
glycine buffer (Sambrook et al., 1989). Gels were transferred to PVDF
membranes at room temperature and blocked overnight at 4 °C in TBS
containing 1% blocking buffer (Roche, Indianapolis, IN). Membranes
were reactedwith anti-GLuc antibody (Nanolight, Pinetop, AZ) or anti-
HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by
an anti-rabbit peroxidase conjugated antibody (Pierce, Rockford, IL).
Blots were processed for ECL using Dura Stable western blotting
reagent (Pierce) then exposed to X-ray ﬁlm (Kodak).
Luciferase-based budding assay
293T cells were transfected with the indicated plasmids using the
following conditions: 0.2 μg DNA, 0.5 μL LF2000 and 1.5×105 cells/96-
well. 96-well plates were also coated with 0.01% poly-lysine (in PBS,
113A.A. Capul, J.C. de la Torre / Virology 382 (2008) 107–114Sigma, St. Louis, MO) to facilitate cell attachment. After 18 h,
transfection mix was changed to DMEM (Invitrogen) containing 5%
FBS. At 48–72 h post-transfection, TCS was collected and clariﬁed by
low-speed centrifugation to remove detached cells. 5–20% of the TCS
(20 μL) was aliquoted to 96-well black plates (VWR, West Chester, PA)
and either an equivalent volume of SteadyGlo luciferase reagent
(Promega, Madison, WI) or 50 μL Gaussia luciferase assay reagent
(New England Biolabs, Ipswich, MA) was added to each well. Fireﬂy
luciferase activity was measured after 10 min incubation at room
temperature using a 10 s read time per well while Gaussia luciferase
activity was read for 5 s following injection of the assay substrate and
a 0.3 s delay per well (Remy and Michnick, 2006). All measurements
were done using a Berthold Centro LB 960 luminometer (Berthold
Technologies, Oak Ridge, TN). To assay Gaussia luciferase activity in
cells, 25 μL of luciferase lysis buffer (NEB) was added to cells in 96-well
plates and lysates were transferred to 96-well black plates for
measurement of GLuc activity. To measure ﬁreﬂy luciferase activity
in cells, 50 μL of SteadyGlo luciferase reagent was added to cells and
incubated for 10 min to achieve lysis. The cell lysate containing FLuc
assay reagent was then transferred to 96-well black plates for
measurement of luciferase activity.
Cell viability assay
Cells were also lysed formeasurement of cell viability using CellTiter
Glo (Promega, Madison, WI), which determines the quantity of ATP
present and, therefore, the presence of metabolically active cells. This
assay utilizes a proprietary luciferase, whose substrate (beetle luciferin)
is not used by GLuc (a coelenterazine-type luciferase) and can therefore
be used to measure viability in GLuc-overexpressing cells with no
interference by GLuc. GLuc measurements were normalized to cell
viability after setting the viability of cells transfected with empty vector
to 1. This normalization was necessary to account for variations in cell
number between wells following transfection.
Pharmacological inhibition of budding
When cells were treated with 2-hydoxymyristic acid, 293T cells
were transfected with plasmid using the following conditions: 125 ng
DNA in 25 μL Opti-MEM (Invitrogen, Carlsbad, CA), 0.31 μL LF2000 in
25 μL Opti-MEM, ca. 8×104 cells per M96 well. Cells were transfected
in the presence of 1) medium, 2) 28 mM DMSO, or 3) 28 mM DMSO/
100 μM 2-hydroxymyristic acid (Cayman Biologicals, Ann Arbor, MI).
Forty-eight hours post-transfection, TCS was collected and clariﬁed
prior to GLuc assays and cells were lysed for measurement of GLuc
activity or cell viability using CellTiter Glo.
siRNA transfection
293Tcellswere transfectedwith a single dose of siRNAusing reverse
transfection where transfection mix is aliquoted to wells prior to the
addition of cells in suspension, a common technique used to deliver
siRNA to cells in high-throughput formats (Opaluch et al., 2007).
Transfection was done using the following conditions: 20 nM siRNA,
0.2 μL RNAiMAX (Invitrogen, Carlsbad, CA), 2×104 cells per 96 well
previously coated with poly-lysine. At 8 h post-transfection, medium
was changed to DMEM containing 1% FBS. At 24 h post-transfection
cells were transfected with pC-Z(WT)-GLuc using the following
conditions: 125 ng DNA total, 0.32 μL LF2000, 50 μL Opti-MEM per
well. Complexes were prepared in Opti-MEM and added directly to the
wells. At 24 h post-transfection, cells were lysed to measure cell
viability (using CellTiter GLO) or GLuc activity and TCS was collected,
clariﬁed, and 20 μL was transferred to black 96-well plates for GLuc
assays. A non-speciﬁc siRNA (control siRNA #1, Ambion, now under
Invitrogen, Carlsbad, CA) was used as a negative control along with an
siRNA targeted against Tsg101 (using the sequence 5′-CAG CTG AGGGCA CTA ATG CAA-3′). To assess budding efﬁciency, we used the
following calculation: GLuc activity (TCS)/([GLuc activity (TCS)]+[ GLuc
activity (CL)]). To assess siRNA transfection efﬁciency, cells were also
transfected with a siRNA directed against the gene KIF11 (Ambion)
using the same conditions as above. Cells that are positively transfected
exhibit a rounded appearance due to knockdown of the cytoskeletal-
related protein KIF11. We observed a strong effect in over 90% of cells
transfected with this siRNA (data not shown).
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